EP4608403A4 - Modulateurs et leurs utilisations - Google Patents

Modulateurs et leurs utilisations

Info

Publication number
EP4608403A4
EP4608403A4 EP23882103.7A EP23882103A EP4608403A4 EP 4608403 A4 EP4608403 A4 EP 4608403A4 EP 23882103 A EP23882103 A EP 23882103A EP 4608403 A4 EP4608403 A4 EP 4608403A4
Authority
EP
European Patent Office
Prior art keywords
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23882103.7A
Other languages
German (de)
English (en)
Other versions
EP4608403A1 (fr
Inventor
Itay Chowers
Sarah Elbaz-Hayoun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Original Assignee
Hadasit Medical Research Services and Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co filed Critical Hadasit Medical Research Services and Development Co
Publication of EP4608403A1 publication Critical patent/EP4608403A1/fr
Publication of EP4608403A4 publication Critical patent/EP4608403A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP23882103.7A 2022-10-24 2023-10-24 Modulateurs et leurs utilisations Pending EP4608403A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263380675P 2022-10-24 2022-10-24
PCT/IL2023/051103 WO2024089691A1 (fr) 2022-10-24 2023-10-24 Modulateurs et leurs utilisations

Publications (2)

Publication Number Publication Date
EP4608403A1 EP4608403A1 (fr) 2025-09-03
EP4608403A4 true EP4608403A4 (fr) 2026-04-01

Family

ID=90830247

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23882103.7A Pending EP4608403A4 (fr) 2022-10-24 2023-10-24 Modulateurs et leurs utilisations

Country Status (3)

Country Link
EP (1) EP4608403A4 (fr)
IL (1) IL320391A (fr)
WO (1) WO2024089691A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0966443B1 (fr) * 1997-02-26 2009-01-28 Pfizer Inc. Derives amines de l'acide heteroaryle-hexanoique, leur preparation, et leur utilisation comme inhibiteurs selectifs du mip-1 alpha par fixation a son recepteur ccr1
CN103357017A (zh) * 2013-03-07 2013-10-23 首都医科大学附属北京同仁医院 met-RANTES在制备治疗遗传性视网膜变性药物中的应用
JP2018127498A (ja) * 2011-01-11 2018-08-16 ディメリックス バイオサイエンス プロプライアタリー リミテッド 併用療法
CN112386696A (zh) * 2019-08-13 2021-02-23 贵州百灵企业集团制药股份有限公司 一种治疗胰岛素抵抗的靶点及其应用
WO2022079322A1 (fr) * 2020-10-16 2022-04-21 Fundació Centre De Regulació Genòmica Thérapie pour lutter contre une maladie dégénérative et un dommage tissulaire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0966443B1 (fr) * 1997-02-26 2009-01-28 Pfizer Inc. Derives amines de l'acide heteroaryle-hexanoique, leur preparation, et leur utilisation comme inhibiteurs selectifs du mip-1 alpha par fixation a son recepteur ccr1
JP2018127498A (ja) * 2011-01-11 2018-08-16 ディメリックス バイオサイエンス プロプライアタリー リミテッド 併用療法
CN103357017A (zh) * 2013-03-07 2013-10-23 首都医科大学附属北京同仁医院 met-RANTES在制备治疗遗传性视网膜变性药物中的应用
CN112386696A (zh) * 2019-08-13 2021-02-23 贵州百灵企业集团制药股份有限公司 一种治疗胰岛素抵抗的靶点及其应用
WO2022079322A1 (fr) * 2020-10-16 2022-04-21 Fundació Centre De Regulació Genòmica Thérapie pour lutter contre une maladie dégénérative et un dommage tissulaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2024089691A1 *
ZENG HUI-YANG ET AL: "The Role of CCR1 Expression in the Retinal Degeneration in rd Mice", CURRENT EYE RESEARCH, vol. 36, no. 3, 28 January 2011 (2011-01-28), pages 264 - 269, XP093367508, ISSN: 0271-3683, DOI: 10.3109/02713683.2010.535133 *

Also Published As

Publication number Publication date
EP4608403A1 (fr) 2025-09-03
WO2024089691A1 (fr) 2024-05-02
IL320391A (en) 2025-06-01

Similar Documents

Publication Publication Date Title
EP4472967A4 (fr) Agents de dégradation d'irak et leurs utilisations
EP4499068A4 (fr) Agents de dégradation d'irak et leurs utilisations
EP4225383A4 (fr) Modulateurs de la proliferation cellulaire et leurs utilisations
EP4368614A4 (fr) Synthèse et utilisation d'agent de dégradation de phosphatase
IL307479A (en) Cbl-b modulators and uses thereof
EP4463166A4 (fr) Agents de dégradation d'irak4 et leurs utilisations
EP4089115A4 (fr) Anticorps anti-tigit et procédé d'utilisation
EP4499149A4 (fr) Agents de dégradation de protéines et leurs utilisations
IL288310A (en) Cot modulators and methods of use thereof
EP4405359A4 (fr) Agents de dégradation de mdm2 et leurs utilisations
EP3710465A4 (fr) Sels et formes cristallines d'un modulateur allostérique positif du gabaa
EP4266395C0 (fr) Feuille d'électrode et son application
EP4332577A4 (fr) Applications de crmp2 et d'anticorps anti-crmp2
EP4106870A4 (fr) Compositions et utilisations thérapeutiques de cannabidiol
IL287384A (en) Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
EP4128940A4 (fr) Omission et ajournement d'émissions de signaux de référence
EP4228647A4 (fr) Modulateurs de malt1 et leurs utilisations
EP4458854A4 (fr) Anticorps gprc5d et son utilisation
EP3917907C0 (fr) Modulateurs de canaux ioniques potassiques et leurs utilisations
EP4504190A4 (fr) Inhibiteurs d'oxadiazole hdac6 et leurs utilisations
EP4406537A4 (fr) Composé à longue chaîne et son utilisation
EP4378952A4 (fr) Lymphocyte t universel et son utilisation
EP4578945A4 (fr) Système crispr-cas13 et son utilisation
EP4596581A4 (fr) Anticorps anti-cd16a et son utilisation
IL311234A (en) Novel combinations of antibodies and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031495000

Ipc: A61K0031496000

A4 Supplementary search report drawn up and despatched

Effective date: 20260302

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/496 20060101AFI20260224BHEP

Ipc: A61P 27/02 20060101ALI20260224BHEP

Ipc: A61P 27/06 20060101ALI20260224BHEP